Results 81 to 90 of about 94,073 (238)

Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms

Haematologica, 2014
According to the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues, myeloproliferative neoplasms (MPN) include chronic myeloid leukemia and the so-called Philadelphia-negative myeloproliferative neoplasms, i.e.
MALCOVATI, LUCA, RUMI, ELISA, CAZZOLA, MARIO   +2 more
openaire   +4 more sources

Extramedullary T-lymphoblastic Crisis in a Myelodysplastic/Myeloproliferative Neoplasm with a t(12;22)/MN1::ETV6 Translocation

, 2023
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are not a single disease, but rather a heterogenous group of entities which are increasingly subclassified according to recurrent genetic abnormalities.
Albertina Nunes, Isabelina Ferreira, Tiago Maia, Joana Desterro, Francesca Pierdomenico, Maria Gomes da Silva, José Cabeçadas, Ana Carolina Freitas, Pierdomenico, Francesca, Gomes da Silva, Maria, Freitas, Ana Carolina, Maia, Tiago, Desterro, Joana, Cabeçadas, José, Ferreira, Isabelina, Nunes, Albertina   +15 more
core   +1 more source

Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in JAK2-mutated myeloproliferative neoplasms

Haematologica, 2017
High mobility group AT-hook 2 (HMGA2) is an architectural transcription factor that is negatively regulated by let-7 microRNA through binding to it’s 3′-untranslated region. Transgenic mice expressing Hmga2 with a truncation of its 3′-untranslated region
Chih-Cheng Chen, Jie-Yu You, Jrhau Lung, Cih-En Huang, Yi-Yang Chen, Yu-Wei Leu, Hsing-Ying Ho, Chian-Pei Li, Chang-Hsien Lu, Kuan-Der Lee, Chia-Chen Hsu, Jyh-Pyng Gau   +11 more
doaj   +1 more source

Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation

Hematology, Transfusion and Cell Therapy, 2018
Background: Cytokines are key immune mediators in physiological and disease processes, whose increased levels have been associated with the physiopathology of hematopoietic malignancies, such as myeloproliferative neoplasms.
Maira da Costa Cacemiro, Juçara Gastaldi Cominal, Raquel Tognon, Natalia de Souza Nunes, Belinda Pinto Simões, Lorena Lôbo de Figueiredo-Pontes, Luiz Fernando Bazzo Catto, Fabíola Traina, Elizabeth Xisto Souto, Fabiana Albani Zambuzi, Fabiani Gai Frantz, Fabíola Attié de Castro   +11 more
doaj   +1 more source

Advanced Lung Cancer Inflammation Index as a Prognostic Inflammation–Nutrition Marker in Appendiceal High‐Grade Pseudomyxoma Peritonei: A 10‐Year Single‐Center Study

ANZ Journal of Surgery, EarlyView.
Among 223 patients with appendiceal high‐grade pseudomyxoma peritonei, a high advanced lung cancer inflammation index (ALI) was independently associated with improved overall survival. A nomogram integrating ALI with clinicopathological and surgical factors showed good discrimination, calibration, and clinical utility for predicting 1‐, 2‐, and 3‐year ...
Yun Gao, Ruiqing Ma, Zhenhai Feng, Siyi Yang, Guangyu An   +4 more
wiley   +1 more source

Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm–Associated Pulmonary Hypertension

, 2019
Myeloproliferative neoplasm (MPN) has been associated with pulmonary hypertension (PH) on the basis of small observational studies, but the mechanism and clinical significance of PH in MPN are not well established.
Kim J., Devereux R. B., Yabut M. M., Brouwer L., Xie L., Weinsaft J. W., Palumbo M. C., Ritchie E. K., Sosner C., Schafer A. I., Rodriguez-Diego S., Silver R. T., Yum B., Krichevsky S., Scandura J. M., Horn E. M.   +15 more
core   +1 more source

Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real‐world evidence

British Journal of Haematology, EarlyView.
Summary Ruxolitinib remains first‐line standard of care for symptomatic myelofibrosis, but resistance/intolerance develops in most patients. Three Janus kinase inhibitors (JAKis) have entered the post‐ruxolitinib space via distinct pivotal trials. We systematically searched prospective trials evaluating JAKi in refractory adults with myelofibrosis ...
Andrea Duminuco, Patrick Harrington, Elena Torre, Hillary Catellani, Novella Pugliese, Matteo Pacilli, Annalisa Santisi, Arianna Sbriglione, Giuseppe A. Palumbo   +8 more
wiley   +1 more source

sj-docx-1-taj-10.1177_20406223221125691 – Supplemental material for Characteristics of myeloproliferative neoplasm-associated portal hypertension and endoscopic management of variceal bleeding

, 2022
Supplemental material, sj-docx-1-taj-10.1177_20406223221125691 for Characteristics of myeloproliferative neoplasm-associated portal hypertension and endoscopic management of variceal bleeding by Xiaoquan Huang, Ming Zhang, Yingjie Ai, Siyu Jiang, Mei ...
Yourong Jian (13849565), Chunqing Zhang (397606), Xiaoquan Huang (9463004), Mei Xiao (1931011), Ming Zhang (9736), Yingjie Ai (11135973), Shiyao Chen (8562999), Yuzheng Zhuge (15889), Lifen Wang (382642), Siyu Jiang (3089550)   +9 more
core   +1 more source

Use of selective serotonin reuptake inhibitors and risk of myeloid malignancy: A nationwide Danish case–control study

British Journal of Haematology, EarlyView.
Summary Preclinical and clinical studies suggest that selective serotonin reuptake inhibitors (SSRIs) can stimulate haematopoiesis by promoting proliferation and mobilization of haematopoietic stem and progenitor cells, but whether SSRI use influences myeloid malignancy risk remains unclear.
Katrine Mose, Anton Pottegård, Mette Reilev, Christen Lykkegaard Andersen, Blánaid Hicks, Mathilde Egelund Christensen   +5 more
wiley   +1 more source

IRF4 dysregulation in chronic myelomonocytic leukemia: another brick in the wall of myelodysplastic/myeloproliferative neoplasms

IRF4 dysregulation in chronic myelomonocytic leukemia: another brick in the wall of myelodysplastic/myeloproliferative ...
Cosimo Cumbo, Elisa Parciante, Luisa Anelli, Francesco Albano, Alessandra Ricco, Crescenzio Francesco Minervini, Maria Rosa Conserva, Antonella Zagaria, Angelo Cellamare, Maria Cristina Nuzzi, Nicoletta Coccaro, Paola Casieri, Francesco Tarantini, Giuseppina Tota, Angela Minervini, Giorgina Specchia, Pellegrino Musto, Immacolata Redavid   +17 more
core   +1 more source